United States · FDA National Drug Code directory
Biktarvy
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 61958-2501_261dcc2a-c849-46b1-abf6-4981ed2c60bc
- Product NDC
- 61958-2501
- Form
- TABLET
- Composition / generic term
- bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate
- Labeler
- Gilead Sciences, Inc.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20180207
- Source listing expiry
- 20271231
Source-listed ingredients
- BICTEGRAVIR SODIUM — 50 mg/1
- EMTRICITABINE — 200 mg/1
- TENOFOVIR ALAFENAMIDE FUMARATE — 25 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 30 TABLET in 1 BOTTLE, PLASTIC (61958-2501-1) · 61958-2501-1
- 7 TABLET in 1 BOTTLE, PLASTIC (61958-2501-2) · 61958-2501-2
- 30 TABLET in 1 BLISTER PACK (61958-2501-3) · 61958-2501-3
- 30 TABLET in 1 BLISTER PACK (61958-2501-5) · 61958-2501-5
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →